Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

COVID-19 Boost As Pharma ROI Hits Heights Not Seen For Seven Years, Finds Deloitte

Executive Summary

Expected return on investment for pharma firms jumped sharply to 7% in 2021, driven largely by COVID-19 R&D but even when the pandemic's impact was stripped out, there was an increase in core R&D productivity compared with 2020, a new report from Deloitte has found. The average cost of developing a drug also declined from 2020 to 2021.

You may also be interested in...



2020 Global Biopharma R&D Productivity And Growth Ranking

The decrease in overall R&D productivity continues – a trend that started in 2018. It would be too easy to attribute this fall in R&D productivity to COVID-19 alone.

Nine Major Approval Decisions To Watch In Early 2022

Nine prominent drug candidates are awaiting an FDA approval decision in the next few months. With the help of Biomedtracker's Early 2022 Outlook Report, we take a look at the potential launches likely to shake up the market from HIV to wet AMD.

Sanofi Pairs Up With Non-Profit Protas In Quest To Cut Clinical Trial Costs

The French major has committed up to £5m for non-profit Protas, which aims to facilitate large clinical studies at a fraction of the usual price and form more pharmaceutical collaborations down the line.

Topics

UsernamePublicRestriction

Register

SC145690

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel